Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicentre, double-blind, randomised, placebo - controlled phase II study to assess efficacy, safety and pharmacokinetics of inhaled Esketamine in subjects with treatment-resistant bipolar depression. Wieloośrodkowe, podwójnie zaślepione, randomizowane, z kontrolą placebo badanie II fazy w celu oceny efektywności, bezpieczeństwa i farmakokinetyki Esketaminy podanej drogą inhalacyjną pacjentom z lekooporną depresją dwubiegunową

Next Previous
Trial Profile

A multicentre, double-blind, randomised, placebo - controlled phase II study to assess efficacy, safety and pharmacokinetics of inhaled Esketamine in subjects with treatment-resistant bipolar depression. Wieloośrodkowe, podwójnie zaślepione, randomizowane, z kontrolą placebo badanie II fazy w celu oceny efektywności, bezpieczeństwa i farmakokinetyki Esketaminy podanej drogą inhalacyjną pacjentom z lekooporną depresją dwubiegunową

Recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Oct 2018

At a glance

  • Drugs Esketamine (Primary)
  • Indications Bipolar depression
  • Focus Therapeutic Use
  • Sponsors Celon Pharma

    • Most Recent Events

    • 25 Oct 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top